Sun Pharma gets 6 USFDA observations for Mohali facility
Advertisement
New Delhi: Drugmaker, Sun Pharmaceutical Industries Limited, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with 6 observations at the company's Mohali manufacturing facility (Punjab, India).
The USFDA conducted an inspection from August 3, 2022 to August 12, 2022.
"At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to USFDA within the stipulated timeline," the company stated in its recent BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.